Filing summary
Entity and period: The supplied filing is Sarcos Technology and Robotics Corporation’s Form 10-K for the fiscal year ended December 31, 2021, signed March 29, 2022. It is not a Palladyne AI Corp. filing, and it reports annual results rather than standalone 2021 fourth-quarter results. The company completed its business combination on September 24, 2021; it was accounted for as a reverse recapitalization, with Old Sarcos treated as the accounting predecessor.
Business context and financial results
Sarcos develops mobile robotic systems intended to augment human strength and dexterity in industrial and hazardous work. Its Guardian S was commercially available; the Guardian XO and Guardian XT, its planned core products, remained in development. The company expected to offer those products mainly through a Robot-as-a-Service subscription model, but reported no RaaS subscription agreements.
| Metric | FY 2021 | FY 2020 |
|---|---|---|
| Revenue | $5.1 million | $8.8 million |
| Cost of revenue | $3.9 million | $5.6 million |
| Gross profit and margin | $1.2 million; 23.8% | $3.2 million; 36.4% |
| Research and development | $17.5 million | $14.1 million |
| General and administrative | $58.1 million | $7.3 million |
| Sales and marketing | $6.6 million | $2.8 million |
| Operating loss | $81.0 million | $21.0 million |
| Net loss | $81.5 million | $20.9 million |
| Net loss per share, basic and diluted | $0.72 | $0.21 |
| Cash used in operating activities | $42.1 million | $16.9 million |
| Cash used in investing activities | $4.7 million | $1.0 million |
Revenue declined 42%. Research and development services revenue fell 47% to $3.6 million as Sarcos narrowed contract work to projects aligned with commercialization; product revenue fell 26% to $1.5 million. Gross margin also declined. Operating expenses rose 189%; general and administrative expense included $41.8 million of stock-based compensation, largely associated with awards vesting or beginning to vest around the business combination.
Cash and cash equivalents were $217.1 million at year-end, versus $33.7 million a year earlier; working capital was $222.2 million. The business combination and PIPE financing generated $228.8 million in net cash proceeds. Management said available cash was expected to fund planned operations for at least 12 months from the report date. Notes payable were zero at year-end after forgiveness of $4.4 million in PPP loans. The balance sheet included $13.7 million of warrant liabilities. Stockholders’ equity was $214.0 million.
Material changes, outlook, and notable items
- Commercial timing is uncertain: Sarcos expected initial commercial production of Guardian XO and Guardian XT by the end of 2022, with initial customer deliveries in early 2023. It warned that supply shortages, higher costs, hiring challenges, product development, safety testing, and manufacturing arrangements could delay those targets.
- Demand remains unproven: The company reported no binding commitments for commercial versions of Guardian XO or Guardian XT and no pending orders for those versions. Prospective customer discussions and interest in thousands of units were not binding orders. All $1.8 million of reported backlog was expected to be recognized in 2022.
- Manufacturing and service model are not established at scale: Sarcos had not signed a definitive agreement with a contract manufacturer, had no high-volume manufacturing experience, and had limited experience servicing products at scale. RaaS adoption, pricing, utilization, maintenance costs, and customer returns remained uncertain.
- Cash commitments: The company disclosed $16.2 million in future operating lease payments and $36.0 million in unconditional Palantir software and services commitments, largely scheduled for 2023–2026. The Palantir agreement had a total stated cost of $42.0 million over six years.
- Subsequent acquisition announcement: On March 28, 2022, Sarcos announced a definitive agreement to acquire RE2, Inc. for approximately $100 million, comprising about $30 million cash and $70 million in Sarcos shares, subject to adjustments and closing conditions. Closing was expected in the second quarter of 2022; it was not included in the reported results.
- Accounting and controls: Sarcos reported that internal control over financial reporting and disclosure controls were not effective as of December 31, 2021 due to a remaining material weakness involving accounting for certain unusual or nonstandard transactions. Management described remediation efforts. The auditor issued an unqualified opinion on the financial statements but did not opine on internal control effectiveness.
- Unusual earnings items: FY 2021 included a $4.9 million noncash warrant fair-value loss and a $4.4 million gain from PPP loan forgiveness. Warrant remeasurement may continue to cause GAAP earnings volatility.
- Contingencies and concentration: The company accrued $0.5 million for estimated settlements of ongoing legal claims and reported no known proceedings expected to have a material adverse effect. Five customers accounted for 87% of 2021 revenue; one customer represented 81% of year-end accounts receivable.
Most important facts for investors to verify
- Confirm the issuer and reporting period: this is Sarcos Technology and Robotics Corporation’s FY 2021 10-K, not a Palladyne AI Corp. filing or a standalone Q4 report.
- Track actual Guardian XO and Guardian XT development, safety validation, manufacturing agreements, production costs, delivery dates, and binding customer orders or subscriptions.
- Monitor cash burn against the company’s stated funding runway, including the disclosed Palantir commitment, lease obligations, and the planned RE2 acquisition’s cash and share consideration.
- Assess progress remediating the material weakness and whether subsequent filings report effective controls or any restatements.
- Review customer concentration and the conversion of government and development contracts into commercial sales; projected market size and customer interest are not contracted revenue.